Stockscreener 앱 받기
10.95
0.64%
-0.07
시간 외 거래:
10.95
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa
Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks
Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN
Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - AOL.com
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV) - TradingView
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire
Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance
Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus
Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus
Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha
Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com
HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener
Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential - TipRanks
Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Verve Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition news - Investing.com
Verve Therapeutics Soars on Groundbreaking LDL-C Data: A New Era for Cardiovascular Gene Editing? - AInvest
M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - The Globe and Mail
Eli Lilly to acquire for Verve Therapeutics for up to $1.3B - MSN
Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover - MSN
Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn - MSN
Why Verve Therapeutics Stock Is Skyrocketing Today - MSN
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - The Mighty 790 KFGO
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say By Reuters - Investing.com
Lilly to acquire Verve Therapeutics for up to $1.3 billion By Investing.com - Investing.com South Africa
Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus
Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus
In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly - Wilson Sonsini
Eli Lilly Eyes $1.3 Billion Deal For Verve Therapeutics - Finimize
Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ
These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More - Barron's
Verve Therapeutics downgraded to Market Perform from Outperform at LifeSci - TipRanks
Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say - MSN
Hold Rating on Verve Therapeutics Amid Acquisition and Development Milestones - TipRanks
0.64%
0.37%
자본화:
|
볼륨(24시간):